New glucagon analogues with conformational restrictions and altered amphiphilicity: Effects on binding, adenylate cyclase and glycogenolytic activities

Victor J Hruby, B. Gysin, D. Trivedi, David G Johnson

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

In an effort to obtain highly potent glucagon antagonists, we have investigated glucagon (1) structure-function relationships utilizing the following design principles: (1) structural changes known to lead to partial agonist activities; (2) conformational restrictions; (3) changes in the conformational probabilities of the primary sequence; and (4) increased amphiphilicity. In this report we present the total synthesis, purification, receptor binding, adenylate cyclase activity, in vivo glycogenolytic activity and CD spectrum of the following four glucagon analogues: [Ahx17,18]glucagon (2), [D-Phe4,Tyr5, 3,5-diiodo- Tyr10,Arg12,Lys17,18,Glu21]glucagon (3), [Asp9,Lys17,18,Glu21]glucagon 4, and [Glu15,Lys17,18]glucagon 5. Compound 2 binds exclusively to the high affinity receptor and compound 3 was a highly potent antagonist with respect to adenylate cyclase activity. Analog 4 showed distinct biphasic binding (IC50 5.6 nM and 630 nM), with only the low affinity binding leading to adenylate cyclase activity. Furthermore in analogue 5 receptor binding and adenylate cyclase activity were dissociated by a factor of 5. The results are consistent with a multistep binding mechanism in which glucagon interacts first nonspecifically with the anisotropic interphase of the cell membrane, followed by a conformational transition which occurs in the sequences 10-14 and 15-18 when the membrane bound peptide binds to its receptor.

Original languageEnglish (US)
Pages (from-to)845-855
Number of pages11
JournalLife Sciences
Volume52
Issue number10
DOIs
StatePublished - 1993

Fingerprint

Glucagon
Adenylyl Cyclases
Interphase
Cell membranes
Inhibitory Concentration 50
Purification
Cell Membrane
Membranes
Peptides

ASJC Scopus subject areas

  • Pharmacology

Cite this

@article{72ed32d2619e4481a52c90388a3bf401,
title = "New glucagon analogues with conformational restrictions and altered amphiphilicity: Effects on binding, adenylate cyclase and glycogenolytic activities",
abstract = "In an effort to obtain highly potent glucagon antagonists, we have investigated glucagon (1) structure-function relationships utilizing the following design principles: (1) structural changes known to lead to partial agonist activities; (2) conformational restrictions; (3) changes in the conformational probabilities of the primary sequence; and (4) increased amphiphilicity. In this report we present the total synthesis, purification, receptor binding, adenylate cyclase activity, in vivo glycogenolytic activity and CD spectrum of the following four glucagon analogues: [Ahx17,18]glucagon (2), [D-Phe4,Tyr5, 3,5-diiodo- Tyr10,Arg12,Lys17,18,Glu21]glucagon (3), [Asp9,Lys17,18,Glu21]glucagon 4, and [Glu15,Lys17,18]glucagon 5. Compound 2 binds exclusively to the high affinity receptor and compound 3 was a highly potent antagonist with respect to adenylate cyclase activity. Analog 4 showed distinct biphasic binding (IC50 5.6 nM and 630 nM), with only the low affinity binding leading to adenylate cyclase activity. Furthermore in analogue 5 receptor binding and adenylate cyclase activity were dissociated by a factor of 5. The results are consistent with a multistep binding mechanism in which glucagon interacts first nonspecifically with the anisotropic interphase of the cell membrane, followed by a conformational transition which occurs in the sequences 10-14 and 15-18 when the membrane bound peptide binds to its receptor.",
author = "Hruby, {Victor J} and B. Gysin and D. Trivedi and Johnson, {David G}",
year = "1993",
doi = "10.1016/0024-3205(93)90513-3",
language = "English (US)",
volume = "52",
pages = "845--855",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - New glucagon analogues with conformational restrictions and altered amphiphilicity

T2 - Effects on binding, adenylate cyclase and glycogenolytic activities

AU - Hruby, Victor J

AU - Gysin, B.

AU - Trivedi, D.

AU - Johnson, David G

PY - 1993

Y1 - 1993

N2 - In an effort to obtain highly potent glucagon antagonists, we have investigated glucagon (1) structure-function relationships utilizing the following design principles: (1) structural changes known to lead to partial agonist activities; (2) conformational restrictions; (3) changes in the conformational probabilities of the primary sequence; and (4) increased amphiphilicity. In this report we present the total synthesis, purification, receptor binding, adenylate cyclase activity, in vivo glycogenolytic activity and CD spectrum of the following four glucagon analogues: [Ahx17,18]glucagon (2), [D-Phe4,Tyr5, 3,5-diiodo- Tyr10,Arg12,Lys17,18,Glu21]glucagon (3), [Asp9,Lys17,18,Glu21]glucagon 4, and [Glu15,Lys17,18]glucagon 5. Compound 2 binds exclusively to the high affinity receptor and compound 3 was a highly potent antagonist with respect to adenylate cyclase activity. Analog 4 showed distinct biphasic binding (IC50 5.6 nM and 630 nM), with only the low affinity binding leading to adenylate cyclase activity. Furthermore in analogue 5 receptor binding and adenylate cyclase activity were dissociated by a factor of 5. The results are consistent with a multistep binding mechanism in which glucagon interacts first nonspecifically with the anisotropic interphase of the cell membrane, followed by a conformational transition which occurs in the sequences 10-14 and 15-18 when the membrane bound peptide binds to its receptor.

AB - In an effort to obtain highly potent glucagon antagonists, we have investigated glucagon (1) structure-function relationships utilizing the following design principles: (1) structural changes known to lead to partial agonist activities; (2) conformational restrictions; (3) changes in the conformational probabilities of the primary sequence; and (4) increased amphiphilicity. In this report we present the total synthesis, purification, receptor binding, adenylate cyclase activity, in vivo glycogenolytic activity and CD spectrum of the following four glucagon analogues: [Ahx17,18]glucagon (2), [D-Phe4,Tyr5, 3,5-diiodo- Tyr10,Arg12,Lys17,18,Glu21]glucagon (3), [Asp9,Lys17,18,Glu21]glucagon 4, and [Glu15,Lys17,18]glucagon 5. Compound 2 binds exclusively to the high affinity receptor and compound 3 was a highly potent antagonist with respect to adenylate cyclase activity. Analog 4 showed distinct biphasic binding (IC50 5.6 nM and 630 nM), with only the low affinity binding leading to adenylate cyclase activity. Furthermore in analogue 5 receptor binding and adenylate cyclase activity were dissociated by a factor of 5. The results are consistent with a multistep binding mechanism in which glucagon interacts first nonspecifically with the anisotropic interphase of the cell membrane, followed by a conformational transition which occurs in the sequences 10-14 and 15-18 when the membrane bound peptide binds to its receptor.

UR - http://www.scopus.com/inward/record.url?scp=0027417418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027417418&partnerID=8YFLogxK

U2 - 10.1016/0024-3205(93)90513-3

DO - 10.1016/0024-3205(93)90513-3

M3 - Article

C2 - 8445980

AN - SCOPUS:0027417418

VL - 52

SP - 845

EP - 855

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 10

ER -